FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2980744478> ?p ?o ?g. }

• W2980744478 endingPage "5389" @default.
• W2980744478 startingPage "5389" @default.
• W2980744478 abstract "Abstract Background: Chimeric antigen receptor-modified T cells (CARTs) targeting CD19 has illustrated therapeutic efficacy in diffuse large B cell lymphoma (DLBCL). However, severe cytokine release syndrome (sCRS) reaction and CAR-T-cell-related encephalopathy syndrome (CRES) are the main adverse reactions of CART therapy. Because of the concern of severe CRES which is associated with potential mortality, patients with primary central nervous system Lymphoma(PCNSL) are excluded in most of CART clinical trials. CD70 is a promising therapeutic target due to the restricted expression pattern in normal tissues and overexpression in some lymphoma tissues, so CD70 specific CARTs maybe avoid CD19-negative relapse .Here we report a case with refractory and relapsed PCNSL who achieved long-term disease-free survival by combination therapy of CD19 and CD70 specific CARTs without inducing CRS or CRES. Methods: CD3+ cells were selected from the apheresis PBMC and activated before lentiviral 4SCAR infection. The cells were transduced with a caspase 9-inducible, safety-engineered lentivector CAR containing anti-CD19 or -CD70 scFv fused with multiple intracellular signaling domains: CD28/CD27/CD3z-iCasp9 (4SCAR19 or 4SCAR70). The quality of apheresis cells, gene transfer and T cell proliferation efficiencies, and effective CAR T infusion dose were quantitatively scored and documented. Tumor sections were immunohistochemically stained with different antibodies including anti-CD19 and anti-CD70 antibodies to confirm antigen expression. The patient received cyclophosphamide and fludarabine conditioning regimen before the dual CARTs cell infusions. Case presentation: A 67-year-old male who was diagnosed as PCNSL of DLBCL in 2011.The patient received 6 cycles of temozolomide and high does methotrexate, and achieved CR. In December 2016 he relapsed and was treated with right frontal lobe space-occupying resection and multi-course chemotherapy including 2 course of rituximab, high dose methotrexate and temozolomide ,and 6 courses of rituximab, high dose methotrexate and ibrutinib,and he achieved remission again.However, He relapsed again in August 2017, with the clinical symptoms of dizziness , fatigue, left corners of the mouth askew and occlusal difficulties.MRI presented a residual mass on the right side of the postoperative cavity of 26mm*35mm*30mm and stale hemorrhage in left basal ganglia. After confirmation for CD19 and CD70 expression in his tumor specimens, the pt enrolled in the clinicaltrail :Combination CART cell therapy targeting hematological malignancies(clinicaltrail.gov registry NCT03125577).He received 4SCAR19 and 4SCAR70 T cells targeting CD19 and CD70 following lymphodepletion chemotherapy with FC regimen conditioning (FLU 30mg/m2, d1-3; CTX 300mg/m2, d1-3) in October 2017. Brain MRI 1 month later showed complete remission and the pt had symptomatic improvement. To date, after more than 8 months of follow-up, the pt remains in CR (figure1) and CART cells still can be detected . There was no CRS or CRES during the treatment and in follow-up period. Conclusions: The study results demonstrate that CARTs are able to pass through the blood-brain barrier without inducing CRS or CRES, suggesting that CNS tumor is not an absolute contraindication to 4sCART therapy. In addition, the combination of CD19 and CD70 specific 4sCARTs could effectively target PCNSL and achieves long-term disease-free survival without sCRS or CRES. Disclosures No relevant conflicts of interest to declare." @default.
• W2980744478 created "2019-10-25" @default.
• W2980744478 creator A5009881958 @default.
• W2980744478 creator A5017056661 @default.
• W2980744478 creator A5023708281 @default.
• W2980744478 creator A5055821124 @default.
• W2980744478 creator A5056820617 @default.
• W2980744478 creator A5071212122 @default.
• W2980744478 creator A5073216396 @default.
• W2980744478 creator A5086762567 @default.
• W2980744478 date "2018-11-29" @default.
• W2980744478 modified "2023-10-16" @default.
• W2980744478 title "Combination of CD19 and CD70 Specific Chimeric Antigen Receptor T Cells Achieves Long-Term Disease-Free Survival in Relapsed and Refractory Primary Central Nervous System Diffuse Large B Cell Lymphoma" @default.
• W2980744478 doi "https://doi.org/10.1182/blood-2018-99-117694" @default.
• W2980744478 hasPublicationYear "2018" @default.
• W2980744478 type Work @default.
• W2980744478 sameAs 2980744478 @default.
• W2980744478 citedByCount "1" @default.
• W2980744478 countsByYear W29807444782019 @default.
• W2980744478 crossrefType "journal-article" @default.
• W2980744478 hasAuthorship W2980744478A5009881958 @default.
• W2980744478 hasAuthorship W2980744478A5017056661 @default.
• W2980744478 hasAuthorship W2980744478A5023708281 @default.
• W2980744478 hasAuthorship W2980744478A5055821124 @default.
• W2980744478 hasAuthorship W2980744478A5056820617 @default.
• W2980744478 hasAuthorship W2980744478A5071212122 @default.
• W2980744478 hasAuthorship W2980744478A5073216396 @default.
• W2980744478 hasAuthorship W2980744478A5086762567 @default.
• W2980744478 hasBestOaLocation W29807444781 @default.
• W2980744478 hasConcept C126322002 @default.
• W2980744478 hasConcept C147483822 @default.
• W2980744478 hasConcept C203014093 @default.
• W2980744478 hasConcept C2776090121 @default.
• W2980744478 hasConcept C2776694085 @default.
• W2980744478 hasConcept C2776755627 @default.
• W2980744478 hasConcept C2778559949 @default.
• W2980744478 hasConcept C2778957590 @default.
• W2980744478 hasConcept C2779263901 @default.
• W2980744478 hasConcept C2779338263 @default.
• W2980744478 hasConcept C2780850621 @default.
• W2980744478 hasConcept C2781173314 @default.
• W2980744478 hasConcept C3875195 @default.
• W2980744478 hasConcept C502942594 @default.
• W2980744478 hasConcept C71924100 @default.
• W2980744478 hasConcept C8891405 @default.
• W2980744478 hasConceptScore W2980744478C126322002 @default.
• W2980744478 hasConceptScore W2980744478C147483822 @default.
• W2980744478 hasConceptScore W2980744478C203014093 @default.
• W2980744478 hasConceptScore W2980744478C2776090121 @default.
• W2980744478 hasConceptScore W2980744478C2776694085 @default.
• W2980744478 hasConceptScore W2980744478C2776755627 @default.
• W2980744478 hasConceptScore W2980744478C2778559949 @default.
• W2980744478 hasConceptScore W2980744478C2778957590 @default.
• W2980744478 hasConceptScore W2980744478C2779263901 @default.
• W2980744478 hasConceptScore W2980744478C2779338263 @default.
• W2980744478 hasConceptScore W2980744478C2780850621 @default.
• W2980744478 hasConceptScore W2980744478C2781173314 @default.
• W2980744478 hasConceptScore W2980744478C3875195 @default.
• W2980744478 hasConceptScore W2980744478C502942594 @default.
• W2980744478 hasConceptScore W2980744478C71924100 @default.
• W2980744478 hasConceptScore W2980744478C8891405 @default.
• W2980744478 hasIssue "Supplement 1" @default.
• W2980744478 hasLocation W29807444781 @default.
• W2980744478 hasOpenAccess W2980744478 @default.
• W2980744478 hasPrimaryLocation W29807444781 @default.
• W2980744478 hasRelatedWork W2809013389 @default.
• W2980744478 hasRelatedWork W2910067912 @default.
• W2980744478 hasRelatedWork W2936186479 @default.
• W2980744478 hasRelatedWork W2980744478 @default.
• W2980744478 hasRelatedWork W3175299903 @default.
• W2980744478 hasRelatedWork W3196726943 @default.
• W2980744478 hasRelatedWork W3208241046 @default.
• W2980744478 hasRelatedWork W4281642551 @default.
• W2980744478 hasRelatedWork W4319870125 @default.
• W2980744478 hasRelatedWork W4385956034 @default.
• W2980744478 hasVolume "132" @default.
• W2980744478 isParatext "false" @default.
• W2980744478 isRetracted "false" @default.
• W2980744478 magId "2980744478" @default.
• W2980744478 workType "article" @default.